Obesity and Weight Loss Strategies for Patients With Heart Failure
JACC: Heart Failure · 2024-09 · 12 (9) · 1509-1527
DOI: 10.1016/j.jchf.2024.06.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JACC: Heart Failure, 2024-09. Verfasst von Amanda R Vest und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Cli…. Hauptthemen laut MEDLINE: Heart Failure, Obesity, Weight Loss, Bariatric Surgery. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 152 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Obesity is a common comorbidity among patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), with the strongest pathophysiologic link of obesity being seen for HFpEF. Lifestyle measures are the cornerstone of weight loss management, but sustainability is a challenge, and there are limited efficacy data in the heart failure (HF) population. Bariatric surgery has moderate efficacy and safety data for patients with preoperative HF or left ventricular dysfunction and has been associated with reductions in HF hospitalizations and medium-term mortality. Antiobesity medications historically carried concerns for cardiovascular adverse effects, but the safety and weight loss efficacy seen in general population trials of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide/GLP-1 agonists are highly encouraging. Although there are safety concerns regarding GLP-1 agonists in advanced HFrEF, trials of the GLP-1 agonist semaglutide for treatment of obesity have confirmed safety and efficacy in patients with HFpEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: vesta2@ccf.org.
- Metamor Metabolic Institute, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
- Friedman School of Nutrition Science and Policy at Tufts University, Boston, Massachusetts, USA.
- Department of Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
- Frances Stern Nutrition Center, Tufts Medical Center, Boston, Massachusetts, USA.
Zitieren
APA
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C. L., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva-deAbreu, A. (2024). Obesity and Weight Loss Strategies for Patients With Heart Failure. JACC: Heart Failure, 12(9), 1509-1527. https://doi.org/10.1016/j.jchf.2024.06.006
Vancouver
Vest AR, Schauer PR, Rodgers JE, Sanderson E, LaChute CL, Seltz J, et al. Obesity and Weight Loss Strategies for Patients With Heart Failure. JACC: Heart Failure. 2024;12(9):1509-1527. doi:10.1016/j.jchf.2024.06.006
BibTeX
@article{Vest2024,
author = {Vest, Amanda R and Schauer, Philip R and Rodgers, Jo E and Sanderson, Emily and LaChute, Courtney L and Seltz, Jessica and Lavie, Carl J and Mandras, Stacy A and Tang, W H Wilson and daSilva-deAbreu, Adrian},
title = {Obesity and Weight Loss Strategies for Patients With Heart Failure},
journal = {JACC: Heart Failure},
year = {2024},
volume = {12},
number = {9},
pages = {1509--1527},
doi = {10.1016/j.jchf.2024.06.006}
}
EUVIMED